CMPX - NASDAQ
Compass Therapeutics, Inc.
$2.13
+2.4%Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotCompass Therapeutics, Inc. Management Team
Ms. Vered Bisker-Leib MBA, Ph.D.
Advisor
Compensation
$1,531,657
Dr. Thomas J. Schuetz M.D., Ph.D.
Chief Executive Officer & Vice Chairman
Compensation
$994,800
Mr. Barry Shin J.D., M.B.A.
Chief Financial Officer
Compensation
$406,256
Anna Gifford
Communications Manager
Mr. Neil L. Lerner CPA
Senior Vice President & Chief Accounting Officer
Dr. Minori Rosales M.D., Ph.D.
Senior Vice President & Head of Clinical Development
Ms. Karin Herrera B.A.
Senior Vice President & Head of Clinical Operations
Mr. Jonathan E. Anderman J.D.
Senior Vice President, General Counsel & Corporate Secretary
Compensation
$541,620
Dr. James Kranz Ph.D.
Vice President and Head of Chemistry Manufacturing & Controls
Compass Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $76K worth of CMPX shares, with no selling activity reported.
3 Months
40.0K
75.60K
0
0.00
+76K
+$76K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Anderman Jonathan
Officer: General Counsel
$47K
Lerner Neil
Officer: Chief Accounting Officer
$28K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $76K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
CMPX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 27, 2023 | June 15, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | May 24, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 03, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.